Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Intellia starts late-stage test of CRISPR therapy for rare swelling disease
Intellia Therapeutics initiates Phase 3 HAELO trial for NTLA-2002, a CRISPR gene editing treatment targeting hereditary angioedema, aiming to reduce attacks and kallikrein protein levels. The trial will involve 60 adults, with a 2-to-1 randomization to NTLA-2002 or placebo, followed by a crossover phase. Intellia seeks to compete with Pfizer, BridgeBio Pharma, and Alnylam in rare disease treatments.
Out Of The Trash Bin: How Cobenfy's Unusual Journey Could Change Pharma
Bristol Myers Squibb's schizophrenia drug, Cobenfy, approved by FDA after 30-year journey from Eli Lilly's Alzheimer's drug xanomeline, could inspire future drug discovery.
Concerns have been raised about obesity treatments, which are attracting attention due to the effect
Regeneron CEO warns obesity drugs cause rapid muscle loss, posing long-term health risks. A JAMA study shows 40% of patients regain weight within a year. Novo Nordisk's WeGovi, a GLP-1 drug, is expected in Korea this month, with a monthly cost of 800,000 won.
Regeneron co-founder warns of harms from weight-loss drugs
The article discusses the use of SSR (Server-Side Rendering) and its implementation through a JavaScript service entry.
Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma
Real-world outcomes of relapsed/refractory multiple myeloma patients treated with cilta-cel showed 89% overall response rate and 70% complete response, despite many being ineligible for the trial leading to its approval. Median 12-month progression-free survival was 68% and overall survival 82%, with similar serious side effects reported.
Should You Buy the Dip on This Top Growth Stock?
Regeneron Pharmaceuticals faces headwinds with Eylea, its key eye disease treatment, due to biosimilar competition and a recent court decision favoring Amgen. Despite this, Regeneron's higher-dose Eylea and growth driver Dupixent, an eczema treatment, suggest resilience. Long-term biotech investors are advised to consider buying Regeneron shares on the dip.
9 Months of Treatment With Tralokinumab Results in Improved QoL, Itch, and Sleep
Nine months of tralokinumab treatment improved itch, sleep quality, and overall quality of life in adult atopic dermatitis patients, according to interim TRACE study results presented at the 2024 EADV Congress.
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
FDA approves Sanofi/Regeneron’s Dupixent for COPD, Eli Lilly invests $4.5B in new Indiana facility, AbbVie seeks FDA approval for lung cancer candidate Teliso-V, and AstraZeneca receives priority review for cancer drugs.
Chronic Urticaria Competitive Landscape Assessment 2024
The 'Chronic Urticaria: Competitive Landscape' report by ResearchAndMarkets.com details the current and future therapeutic market, highlighting key players like Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair). With over 60 million diagnosed cases in 16 countries, the report covers 42 pipeline molecules, including 3 in Phase III and 17 in Phase II. The US leads in trial sites for chronic urticaria, followed by China. The report also analyzes acquisition deals and provides strategic insights for market players.
Global LAG 3 Antibody FDA Approval Clinical Trials
Global LAG-3 Inhibitors Market expected to exceed USD 3 billion by 2029; Opdualag, first LAG-3 therapy, approved for melanoma. LAG-3 inhibitors show potential in combination therapies for various cancers and diseases. Key players include Bristol Myers Squibb, Roche, and Regeneron. Market valued at USD 625 million in 2023, projected to grow significantly.
© Copyright 2024. All Rights Reserved by MedPath